Pfizer Seagen Initiates Global Phase 3 Trial for ADC ‘PF-XXX’ in Platinum-Resistant Ovarian Cancer
Clinical Trials Arena USA Overview Pfizer Seagen has initiated a global Phase 3 clinical trial for its investigational antibody-drug conjugate (ADC), 'PF-XXX,' in patients with platinum-resistant ovarian cancer. The trial aims to evaluat...
